Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.

Item

http://www.wikidata.org/entity/Q37481450

Q37481450

about

Expression of OATP family members in hormone-related cancers: potential markers of progression Gene expression variability in human hepatic drug metabolizing enzymes and transporters Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.Safety of statins: an update Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.Statin drug interactions and related adverse reactions.Review article: prescribing medications in patients with cirrhosis - a practical guide.Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice.Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: Studies in Oatp1b2-null mice.Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry.Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment.Retracted: Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans.Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.ABCG transporters and disease.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.Update information on drug metabolism systems--2009, part I.The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.Genetic polymorphisms in placental transporters: implications for fetal drug exposure to oral antidiabetic agents.Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis.Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.Pharmacogenetics of drug transporters in the enterohepatic circulation.The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Renal transport of organic anions and cations.Germline pharmacogenetics of paclitaxel for cancer treatment.Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.

P2860

Q21091035-A1CDF50F-E7EB-4630-94EB-FBD9BBD6E190 Q28486732-3CF3EE1F-96EF-4EB9-82C0-676167516740 Q30511951-49748681-FA9A-49C8-AAF9-B9C4B90FD527 Q33434697-ECC6A678-5558-41EB-B07E-A28C4B6AC411 Q33949312-7C36EE14-C9CF-4012-85F5-8085D7C3766D Q34138321-D5236A43-352B-4B46-8913-EAF8B93CCC69 Q34292468-54245303-F066-4F1E-A4B8-0C1424F1CB3F Q34342554-525B35FE-71B0-4AD5-AD73-4BB699EB4682 Q34565278-D99EE7DE-FF92-4ECD-A584-8D58258E6D07 Q34571070-702EE971-F0AE-4106-A24A-00D5C3E93EDC Q34613443-6DF5300A-C3CC-410D-8A79-A758A3956484 Q34631971-6FD1E6A5-341A-45DB-A054-2CE017635C22 Q34680467-AF5A64B2-29F7-49BF-BC82-C0678F71258C Q35264245-F9BB167E-C140-4FC4-AE94-9081EC4DD7E0 Q35297067-BC0437DA-D707-4678-841C-B2DF05862C42 Q35501523-F4BDC1F0-AF45-4DC8-852C-AC1BC1363762 Q35781894-83117544-1948-41A8-AF9A-1DC3FBE7DF48 Q35913104-A4F8E2A8-03F4-42FD-8A93-457B2626683F Q36111214-DD7CBD49-C8D2-424C-B6C8-63095708E5D1 Q36233941-D9793137-DF04-40A3-91A2-DF9EC5B9F4FE Q36852518-AA7D5E87-0D8A-45A5-A0F2-D0517254A922 Q36924687-7A22B9C6-B901-4488-8EA1-3E9AF7DE2D9E Q37099947-DA52716E-4727-499C-8CF8-C4BFDDDA0D2D Q37121662-30892B01-F37E-4494-88B8-1E3138D67106 Q37680968-3F033FE6-5B2D-48CE-9932-AD135883CA62 Q37716030-ADBDF3CA-A3FC-49F9-8F5C-FDA6DCCB3B78 Q37810986-6907C27E-0AFB-46FD-810E-9CDD1621EC67 Q37830057-3597835B-384D-448C-B4B7-25A44436DCD9 Q37841614-2120F27B-1D66-4272-8F85-995338117752 Q37855801-B35A5C15-AE1A-4DC7-868D-9EC29D6FAC7B Q37880875-2EA5EC3D-9ABD-480B-B206-275A757412A6 Q37955160-71A7E828-CF3F-4813-9DC5-C1F0059DE48E Q37960129-B3B7C992-6C15-4955-AC9D-DB83A0682EDE Q38003174-B10491F9-35BC-4BDD-AC6E-85C660EA48BB Q38056878-A7E0F796-6EF0-4474-84B5-597E881D7B7F Q38071700-E908B85C-0E5E-4722-BABE-A078B546C7C6 Q38109095-2E463051-CC0A-4FA1-90C4-7CE67F2482CC Q38111725-C7C4899D-77A1-4EAD-BAE7-71A9D0797AEA Q38120289-BA431677-D1C2-4A65-9B72-6408620ABC72 Q38155218-0CCA74F5-4E63-4BC4-A56D-FBEB3C0E4323

P2860

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.

Item

http://www.wikidata.org/entity/Q37481450

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs